GLP-1 by Condition: PCOS, OSA, MASH, CKD, T2D, CV Disease

GLP-1 receptor agonists were developed for type 2 diabetes, then proved disease-modifying in obesity. Over the last five years, randomized trials have extended the evidence base into cardiovascular disease, sleep apnea, kidney disease, fatty liver, and PCOS. This hub maps the conditions where GLP-1 therapy has the strongest evidence — and where it does not.

Key facts

FDA-approved indications now include: type 2 diabetes, obesity, cardiovascular event prevention (semaglutide 2.4 mg), and moderate-to-severe obstructive sleep apnea in adults with obesity (tirzepatide).
Strong off-label evidence: MASH/NAFLD, PCOS-associated insulin resistance, diabetic kidney disease (semaglutide FLOW trial), HFpEF (STEP-HFpEF).
Compounded semaglutide and tirzepatide (NexLife: $145–$165/mo flat-rate semaglutide; $186–$215/mo flat-rate tirzepatide) are off-label for most non-FDA-approved uses; clinical judgment and informed consent govern.

Conditions covered

GLP-1 & Type 2 Diabetes

The original indication. A1c reduction of 1.5–2.0%, weight loss, and cardiovascular benefit in patients with established disease.

GLP-1 & Cardiovascular Disease

SELECT trial (2023) showed 20% MACE reduction in adults with obesity but without diabetes. First non-diabetes CV indication for a weight-loss drug.

GLP-1 & Sleep Apnea

Tirzepatide became the first drug approved for OSA in adults with obesity (December 2024) after SURMOUNT-OSA showed ~30 events/hr reduction in AHI.

GLP-1 & Fatty Liver (NAFLD/MASH)

Semaglutide phase 3 (ESSENCE, 2024) showed resolution of steatohepatitis without worsening fibrosis — a major MASH endpoint.

GLP-1 & Kidney Disease

FLOW trial (NEJM, 2024) showed semaglutide reduced major kidney events by 24% in adults with T2D and CKD. Stopped early for efficacy.

GLP-1 & PCOS

No FDA indication, but multiple small RCTs show improvement in insulin resistance, weight, hyperandrogenism, and menstrual regularity in PCOS.

How we evaluate the evidence

For each condition we distinguish FDA-approved indications (where the agent has been studied at scale in the target population and approved by regulators) from off-label evidence (where smaller trials or secondary analyses suggest benefit but a formal indication does not yet exist). We cite the primary trial, the effect size, and the population studied — not just the topline number.

See our research bibliography for the full list of trials we cite, and our myths vs. facts page for claims we have specifically fact-checked.

Looking for a provider?

Our top-rated telehealth provider, NexLife, prescribes compounded semaglutide and tirzepatide through state-licensed pharmacies. Flat-rate pricing: $145–$165/mo (sema), $186–$215/mo (tirz). Read our full NexLife review.

Visit NexLife →